Novo Nordisk Expands Wegovy Label in Singapore with Higher Dose Backed by STEP UP Data
Event summary
- Novo Nordisk updated the Singapore label for Wegovy (semaglutide) to include a higher dose of 7.2 mg, supported by data from the STEP UP trial.
- Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks, with mean weight loss reaching 21%.
- Reduction in fat mass constituted up to 84% of weight loss, highlighting improvements in body composition.
- The STEP UP trial included approximately 1,400 adults with obesity and demonstrated significant reductions in impulsive food-related behaviors.
The big picture
Novo Nordisk's label update for Wegovy in Singapore underscores a strategic shift towards higher-dose obesity treatments backed by robust clinical evidence. This move aligns with broader industry trends emphasizing long-term, individualized management of chronic diseases like obesity. The focus on fat mass reduction and appetite control highlights the evolving standards for effective weight management therapies.
What we're watching
- Regulatory Expansion
- Whether Novo Nordisk can secure similar label updates in other markets, expanding the reach of the higher dose semaglutide.
- Clinical Efficacy
- How sustained weight loss and improvements in body composition will impact long-term patient outcomes and healthcare costs.
- Market Competition
- The pace at which competitors like Eli Lilly respond with their own obesity treatments, potentially intensifying the GLP-1 receptor agonist market.
Related topics